To investigate whether the delivery of Foxf1 could reverse persistent PAH, we used a tagged AAV vector, AAV2-ESGHGYF, that specifically targets an increase in expression of Foxf1 to the pulmonary vascular endothelium23. Here, FOXF1 is linked to pulmonary arterial hypertension.